News >

Expert Highlights Potential of Zanubrutinib in Waldenstrom Macroglobulinemia

Jason Harris
Published: Friday, Aug 24, 2018

Judith Trotman, MBChB, FRACP, FRCPA

Judith Trotman, MBChB, FRACP, FRCPA

Zanubrutinib (BGB-3111), an investigational small molecule inhibitor of BTK, showed promising activity in patients with Waldenström macroglobulinemia (WM), according to updated results presented at the 2018 European Hematology Association Congress.

Trotman discussed zanubrutinib’s effect on patient quality of life and how the BTK inhibitor can be used to extend survival for younger patients with WM.

OncLive: Please explain the rationale behind this study.

Trotman: This is a phase I study of zanubrutinib, a next-generation BTK inhibitor with, we believe, greater specificity, less off-target effects, and fewer side effects than the first-generation BTK inhibitors. This is a study primarily to address safety, but as there are more than 300 patients, we're acquiring quite a lot of efficacy data as well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication